Why Standard Blood Panels Fall Short
The typical annual physical produces a metabolic panel and a lipid panel. You receive a total cholesterol number, LDL-C, HDL, triglycerides, fasting glucose, and a few kidney and liver markers. Your doctor compares these to population reference ranges — values calibrated so that 95% of people fall within "normal." The problem: normal is not optimal. In an era of chronic metabolic disease, normal is average — and average is metabolically sick.
Peter Attia's "Medicine 3.0" framework reframes preventive medicine around marginal decade thinking: the goal is not simply to live longer, but to preserve function and healthspan into your 80s and 90s. That requires identifying risk decades earlier than symptoms appear. The 10 markers below are the core of that approach.
The 10 Biomarkers — What They Measure and Why They Matter
1. ApoB — Atherogenic Particle Count
Apolipoprotein B is the protein that coats every atherogenic lipoprotein particle — LDL, VLDL, and IDL. Because each particle carries exactly one ApoB molecule, the ApoB number is a direct count of the particles capable of penetrating arterial walls and initiating atherosclerosis. LDL-C measures the cholesterol cargo, not the vehicle count. Two people with identical LDL-C of 120 mg/dL can have ApoB values differing by 50% — dramatically different cardiovascular risk.
Large-scale Mendelian randomization studies and the INTERHEART trial confirm ApoB is more predictive of cardiovascular events than LDL-C, non-HDL cholesterol, or the total-to-HDL ratio. Statins, PCSK9 inhibitors, and dietary changes (replacing saturated fat with unsaturated, reducing refined carbohydrates) all reduce ApoB. Omega-3 supplementation at 2–4g EPA/DHA per day reduces ApoB modestly but meaningfully.
<80 mg/dL (borderline)
2. hsCRP — High-Sensitivity C-Reactive Protein
C-reactive protein is produced by the liver in response to systemic inflammation. The high-sensitivity assay (hsCRP) detects chronic low-grade inflammation that standard CRP misses entirely. Chronic inflammation is implicated in cardiovascular disease, cancer, neurodegeneration, and accelerated biological aging.
The landmark JUPITER trial demonstrated that statin therapy reduced cardiovascular events significantly in patients with normal LDL-C but elevated hsCRP — establishing hsCRP as an independent risk factor, not merely a surrogate. Primary drivers of elevated hsCRP include visceral adiposity, poor sleep, ultra-processed foods, smoking, periodontal disease, and sedentary behavior. High-dose omega-3s, resistance training, and anti-inflammatory dietary patterns (Mediterranean, whole-food) are evidence-based interventions.
3–10 mg/L (moderate)
3. HbA1c — 3-Month Glucose Average
Hemoglobin A1c measures the percentage of hemoglobin glycated by glucose over the preceding 90 days — a rolling average of glucose exposure. It is the standard diagnostic marker for pre-diabetes (≥5.7%) and diabetes (≥6.5%). The problem: the "normal" ceiling of 5.7% permits years of cumulative glycation damage before a diagnostic threshold is crossed.
Glycation — the non-enzymatic binding of glucose to proteins — damages arterial walls, nerves, kidneys, and the lens of the eye. It accelerates biological aging as measured by epigenetic clocks. Longevity-focused practitioners target HbA1c in the 4.8–5.2% range, reflecting not just absence of disease but active glucose control.
At-home HbA1c test kits allow you to monitor between annual checkups — especially valuable when making dietary changes or experimenting with continuous glucose monitors.
5.7–6.4% (pre-diabetes)
4. Fasting Insulin & HOMA-IR — The Early Warning You're Not Getting
Fasting insulin is arguably the single most important metabolic marker almost no standard panel includes. Insulin is a storage hormone: chronically elevated insulin (hyperinsulinemia) drives fat accumulation, inflammation, cardiovascular disease, and accelerated aging — independently of glucose levels. The pancreas compensates for insulin resistance by producing more insulin, keeping glucose "normal" for years or decades while the underlying resistance worsens.
HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) quantifies this. The formula: fasting insulin (μIU/mL) × fasting glucose (mg/dL) ÷ 405. A result above 1.0 suggests emerging insulin resistance; above 2.9 indicates significant resistance. Standard labs flag fasting insulin only above 25 μIU/mL — a threshold that allows a decade of progressive metabolic dysfunction to go undetected.
HOMA-IR not routinely calculated
HOMA-IR <1.0
5. Fasting Triglycerides — The Insulin Resistance Proxy
Triglycerides are directly driven by carbohydrate intake and insulin signaling. Elevated fasting triglycerides reflect hepatic overproduction of VLDL — a downstream consequence of insulin resistance and excess dietary carbohydrate. The triglyceride-to-HDL ratio (trig:HDL) is one of the most accessible proxies for insulin resistance and small, dense LDL particle dominance.
A trig:HDL ratio below 1.5 (using mg/dL values) generally correlates with large, buoyant LDL particles and good insulin sensitivity. Above 3.5 suggests predominantly small, dense LDL — the phenotype most strongly associated with atherosclerosis. This ratio is calculable from any standard lipid panel, costs nothing additional, and is more informative than total cholesterol alone.
<200 mg/dL (borderline)
Trig:HDL ratio <1.5
6. Lp(a) — The Genetic Wildcard
Lipoprotein(a) — pronounced "L-P-little-a" — is a modified LDL particle with an additional protein called apolipoprotein(a) attached. It is highly atherogenic and thrombogenic: it promotes both plaque formation and blood clotting. Critically, Lp(a) is almost entirely genetically determined. Lifestyle interventions, diet, exercise, and even statins have negligible effect on Lp(a) levels.
Approximately 20% of the global population carries significantly elevated Lp(a) (>50 mg/dL or >125 nmol/L), conferring two- to four-fold increased cardiovascular risk. Because it is genetically fixed, you only need to test it once in your lifetime — but you absolutely should. RNA interference therapies specifically targeting Lp(a) (pelacarsen, olpasiran) are in late-stage trials. Knowing your level now positions you to access these therapies as they reach approval.
(rarely tested)
Test once in lifetime
7. Homocysteine — Methylation and Vascular Health
Homocysteine is an amino acid produced during methionine metabolism. Elevated homocysteine damages arterial endothelium, promotes atherosclerosis, and is independently associated with cognitive decline and dementia — even in the absence of traditional cardiovascular risk factors. It is a functional marker of methylation capacity, the biochemical process underpinning DNA repair, gene expression, and neurotransmitter synthesis.
The most common driver of elevated homocysteine is deficiency in B vitamins — specifically B12, folate (B9), and B6, which are cofactors in homocysteine clearance. Treatment is straightforward: targeted B-vitamin supplementation. A meta-analysis in the Cochrane Database confirms B-vitamin supplementation meaningfully reduces homocysteine. The VITACOG trial demonstrated that lowering homocysteine with B vitamins slowed brain atrophy in subjects with mild cognitive impairment.
Rarely flagged below 12
8. Vitamin D (25-OH) — The Hormone Masquerading as a Vitamin
Vitamin D3 is technically a steroid hormone precursor that regulates over 1,000 genes involved in immune function, calcium metabolism, cardiovascular health, and cancer suppression. Deficiency is epidemic: an estimated 40% of American adults are deficient by conservative standards, and the majority do not reach levels associated with longevity benefit.
Standard clinical labs flag deficiency below 20 ng/mL. Longevity-oriented practitioners target 40–60 ng/mL based on the body of observational evidence associating this range with optimal immune function, reduced cancer incidence, and cardiovascular protection. Vitamin D should be measured twice yearly — spring and fall — to capture seasonal variation, as levels drop significantly in winter months. Testing is inexpensive and often included in direct-to-consumer panels.
<12 ng/mL (deficient)
Test twice yearly
9. Ferritin — Iron Stores and Oxidative Stress
Ferritin is the primary iron storage protein — but it also doubles as an acute-phase reactant, rising during inflammation. This dual nature makes interpretation nuanced. Very low ferritin causes fatigue, cognitive impairment, and anemia. But very high ferritin is equally problematic: excess iron is a potent pro-oxidant, catalyzing free radical production via the Fenton reaction and accelerating cellular damage.
Elevated ferritin can signal iron overload (including genetic hemochromatosis, affecting 1 in 200 people of Northern European descent), chronic inflammation, fatty liver disease, or metabolic syndrome. Standard lab ranges are extremely wide — often up to 300 ng/mL for men — allowing significant iron accumulation before flagging. Longevity practitioners aim for the lower half of physiological range. Regular blood donation, if safe, is one of the most effective ways to reduce excess iron stores.
Women: 11–307 ng/mL
Women: 20–80 ng/mL
10. Free Testosterone + SHBG — The Aging Hormone Axis
Testosterone — present in both sexes — is a critical longevity hormone. Declining testosterone accelerates sarcopenia (muscle loss), increases visceral fat, impairs cognitive function, reduces bone density, and raises cardiovascular risk. Total testosterone alone is insufficient: sex hormone-binding globulin (SHBG) binds testosterone, rendering it biologically inactive. Free testosterone — unbound, bioavailable — is what actually reaches tissues.
SHBG rises with age, insulin sensitivity improvement, and liver health — paradoxically, improving metabolic health can raise SHBG and lower free testosterone even as total testosterone stays stable. Tracking both markers over time reveals whether declining free testosterone is driven by hypogonadism (primary or secondary) or simply rising SHBG. Resistance training, adequate sleep (7–9 hours), zinc and magnesium sufficiency, and maintaining healthy body fat are primary lifestyle levers.
Free T: often not reported
Track trend over time; SHBG 20–50 nmol/L
Reference Range Table — Standard vs. Longevity Optimal
| Biomarker | Standard "Normal" | Longevity Optimal | Primary Driver | Covered by Ins. |
|---|---|---|---|---|
| ApoB | <100 mg/dL | <60 mg/dL | Saturated fat, refined carbs, genetics | Sometimes |
| hsCRP | <3.0 mg/L | <1.0 mg/L | Visceral fat, sleep, diet, smoking | Sometimes |
| HbA1c | <5.7% | 4.8–5.2% | Carbohydrate intake, metabolic health | Yes |
| Fasting Insulin | 2–25 μIU/mL | <5–7 μIU/mL | Carbohydrate, body fat, inactivity | Rarely |
| HOMA-IR | Not calculated | <1.0 | Insulin resistance | No |
| Fasting Triglycerides | <150 mg/dL | <100 mg/dL | Refined carbs, alcohol, insulin resistance | Yes |
| Trig:HDL Ratio | Not calculated | <1.5 | Metabolic health | No |
| Lp(a) | Not routinely tested | <30 mg/dL | Genetics (not modifiable) | Rarely |
| Homocysteine | <15 μmol/L | <7 μmol/L | B12/folate/B6 deficiency | Sometimes |
| Vitamin D (25-OH) | >20 ng/mL | 40–60 ng/mL | Sun exposure, supplementation | Sometimes |
| Ferritin | Men: 24–336 ng/mL | Men: 50–100 ng/mL | Iron intake, inflammation, genetics | Yes |
| Free Testosterone | Often unreported | Upper quartile for age | Sleep, body comp, SHBG levels | Sometimes |
| SHBG | 10–80 nmol/L | 20–50 nmol/L | Liver health, metabolic status | Sometimes |
Getting Tested: Costs, Coverage, and Direct-to-Consumer Options
The majority of longevity biomarkers — ApoB, fasting insulin, Lp(a), homocysteine, HOMA-IR — are not included in standard insurance-covered annual blood work. Ordering them through a primary care physician requires a doctor willing to order non-standard tests, and even then, insurance often denies coverage, leaving you with an unpredictable bill.
Three direct-to-consumer platforms have emerged as the practical solution:
Marek Health
Marek Health offers physician-supervised comprehensive panels built for longevity optimization. Panels include ApoB, Lp(a), fasting insulin, hsCRP, homocysteine, sex hormones, and full thyroid panels. Results come with physician review options. Pricing is transparent upfront — typically $150–400 for comprehensive panels — often cheaper than the co-pay plus surprise billing of a standard office visit for non-covered tests.
Ulta Lab Tests
Ulta Lab Tests offers à la carte ordering from major labs (LabCorp, Quest). You can build a custom panel — ordering only ApoB ($29), fasting insulin ($28), Lp(a) ($39), and homocysteine ($35) — for under $150 total. Blood draw occurs at any LabCorp or Quest patient service center. No physician appointment required. Results are uploaded to your account within 1–3 business days.
Function Health
Function Health, co-founded with Peter Attia's involvement, offers 100+ biomarkers tested twice yearly. The annual membership (~$499) includes comprehensive metabolic, cardiovascular, hormonal, thyroid, and nutrient panels interpreted with reference ranges calibrated for health optimization, not just disease diagnosis. For someone committed to Medicine 3.0 tracking, this represents exceptional value per biomarker.
The LongevityLab Blood Panel Protocol
- 01 Establish baseline now. Order a comprehensive longevity panel via Marek Health, Ulta Lab Tests, or Function Health. Include: ApoB, hsCRP, HbA1c, fasting insulin + glucose (for HOMA-IR), Lp(a), homocysteine, 25-OH Vitamin D, ferritin, free testosterone + SHBG. Total cost: $150–400 out-of-pocket.
- 02 Calculate HOMA-IR immediately. Divide (fasting insulin × fasting glucose) by 405. If HOMA-IR exceeds 1.5, metabolic intervention — carbohydrate reduction, time-restricted eating, resistance training — should be prioritized above all other targets.
- 03 Identify your primary driver. High ApoB + high triglycerides + high fasting insulin = insulin resistance driving atherogenic dyslipidemia. Target metabolic health first. High ApoB with normal insulin = dietary saturated fat or genetic hypercholesterolemia — dietary change or statin discussion with physician.
- 04 Intervene on hsCRP. If hsCRP exceeds 1.0 mg/L, systematically address: sleep quality (7–9 hours), visceral adiposity (ApoB and insulin targets overlap here), ultra-processed food elimination, and oral hygiene. Re-test in 90 days.
- 05 Know your Lp(a) once. If elevated (>30 mg/dL or >75 nmol/L), discuss with a preventive cardiologist. Treat all other modifiable risk factors more aggressively. Consider monitoring emerging RNA interference therapies.
- 06 Retest annually or 3 months post-intervention. Track trends over time, not single data points. A single elevated hsCRP may be acute illness. A consistently elevated hsCRP despite lifestyle optimization warrants deeper investigation.
- 07 Use at-home monitoring between labs. HbA1c test kits and continuous glucose monitors provide real-time data on glycemic response. Omega-3 supplementation for ApoB reduction takes 6–8 weeks to reflect in labs — track compliance with at-home tools.
Interpreting Results: What Moves Which Markers
Understanding which interventions affect which biomarkers prevents the common mistake of applying generic "healthy lifestyle" advice without targeting specific deficits. The table below is a simplified cause-and-effect map:
ApoB and LDL-C: Respond to saturated fat reduction, soluble fiber increase, PCSK9 inhibitors, statins, ezetimibe, and weight loss. Omega-3s lower triglycerides and VLDL-derived ApoB. Time-restricted eating reduces postprandial lipemia.
hsCRP: Responds most dramatically to visceral fat reduction, sleep optimization, and elimination of ultra-processed foods. High-dose omega-3s reduce hsCRP modestly. Statins have independent anti-inflammatory effects beyond lipid lowering — this is the mechanism behind the JUPITER trial findings.
Fasting insulin and HOMA-IR: The single most responsive cluster of markers. Even 5–10% body weight reduction, carbohydrate restriction, or 3 months of consistent resistance training produces dramatic improvements. Time-restricted eating (16:8 or similar) reduces fasting insulin within weeks.
Homocysteine: Methylated B vitamins — methylfolate, methylcobalamin (B12), and pyridoxal-5-phosphate (B6) — are the primary intervention. Response is typically seen within 6–8 weeks of adequate dosing. Testing MTHFR genetic variants can explain non-response to standard folic acid supplementation.
Ferritin: If elevated due to iron overload, therapeutic phlebotomy (blood donation) is the fastest and most effective intervention. If elevated due to inflammation, the underlying inflammatory driver — visceral fat, alcohol, processed foods — must be addressed first.
The Medicine 3.0 Mindset Shift
Peter Attia describes the core shift of Medicine 3.0 as moving from reactive to proactive — from treating disease after it manifests to identifying and addressing risk before it becomes disease. A 55-year-old with a heart attack has had decades of subclinical atherosclerosis. A 45-year-old with a dementia diagnosis has had 20 years of amyloid accumulation. Standard medicine catches these at the finish line. Medicine 3.0 intercepts them at the starting gun.
The 10 biomarkers above are not exotic or experimental. They are available today, mostly for under $300 total, from any major lab. They are validated by decades of peer-reviewed research. They identify risk a decade or more before standard diagnostic markers are affected. The only barrier is knowing to ask for them.
Your next step is simple: order a baseline panel. Establish your personal numbers. Everything else — dietary changes, supplementation, exercise programming, medication discussions with your physician — flows from knowing where you actually stand.